ArticleAntibodies (Basel, Switzerland)2016
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.
Open access · goldAbstract read
In one paragraph
Article in Antibodies (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 94 citations in OpenAlex.
- Review
- Article
- Emerging Role of Bispecific Antibodies in Precision Medicine, Cancer and Modern Therapeutics.Current oncology reports · 2026Review
- Bispecific antibodies and CAR T cells targeting a TP53 mutation-associated neoantigen show discordant affinity requirements.The Journal of clinical investigation · 2026Article
- An Overview on T-Cell Engagers: The Current Position in Both the Biological and Mathematical Context.Computational and structural biotechnology journal · 2026Review
- CDH3 in human tumors: tumor biology and potential therapeutic target.Frontiers in pharmacology · 2026Review
- Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies.Antibodies (Basel, Switzerland) · 2025Review
- A Strategy for Simultaneous Engineering of Interspecies Cross-Reactivity, Thermostability, and Expression of a Bispecific 5T4 x CD3 DARTAntibodies (Basel, Switzerland) · 2025Article
- Design and engineering of bispecific antibodies: insights and practical considerations.Frontiers in bioengineering and biotechnology · 2024Review
- Article
- Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies.Heliyon · 2023Article
- A high throughput bispecific antibody discovery pipeline.Communications biology · 2023Article
- Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy.Frontiers in immunology · 2023Review
- Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia.Journal for immunotherapy of cancer · 2022Article
- Shortened Hinge Design of Fab x sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing of Tumor Cells.Biomolecules · 2022Article
- Bispecific antibody-derived molecules to target persistent HIV infection.Journal of virus eradication · 2022Article
- Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma.Molecular oncology · 2022Article
- Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186.Journal for immunotherapy of cancer · 2022Article
- Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer.Molecular cancer therapeutics · 2022Article
- Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors at 3 institutions in 2 countries.
Adam R RootGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. adam.root@pfizer.com.ORCID 0000-0001-9524-1066
Wei CaoGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. wei.cao@pfizer.com.
Bilian LiGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. bilian.li@pfizer.com.
Peter LaPanGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. peter.lapan@pfizer.com.
Caryl MeadeGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. caryl.meade@pfizer.com.
Jocelyn SanfordGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. jocelyn.sanford@gmail.com.ORCID 0000-0003-3378-422X
Macy JinGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. macy.jin@pfizer.com.
Cliona O'SullivanGlobal Biotherapeutics Technologies, Pfizer Inc., Grange Castle Business Park, Clondalkin, Dublin 22, Ireland. cliona_2000@yahoo.ie.
Emma CumminsGlobal Biotherapeutics Technologies, Pfizer Inc., Grange Castle Business Park, Clondalkin, Dublin 22, Ireland. emmacummins@hotmail.com.
Matthew LambertGlobal Biotherapeutics Technologies, Pfizer Inc., Grange Castle Business Park, Clondalkin, Dublin 22, Ireland. matthew.lambert@pfizer.com.
Alfredo D SheehanGlobal Biotherapeutics Technologies, Pfizer Inc., Grange Castle Business Park, Clondalkin, Dublin 22, Ireland. alfredo.sheehan@pfizer.com.
Weijun MaGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. weijun.ma@pfizer.com.
Scott GattoGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. scott.gatto@pfizer.com.
Kelvin KernsGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. kelvin.kerns@pfizer.com.
Khetemenee LamGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. nee.lam@pfizer.com.
Aaron M D'AntonaGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. aaron.dantona@pfizer.com.ORCID 0000-0003-0063-5594
Lily ZhuGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. lily.zhu@pfizer.com.
William A BradyGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. wmabrady@gmail.com.
Susan BenardGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. susan.benard@pfizer.com.
Amy KingGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. amy.king@pfizer.com.
Tao HeGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. tao.he@pfizer.com.
Lisa RacieGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. lisa.racie@pfizer.com.
Maya AraiGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. maya.arai@pfizer.com.
Dianah BarrettGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. dianah.barrett@pfizer.com.
Wayne StochajGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. wayne.stochaj@pfizer.com.
Edward R LaVallieGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. edward.lavallie@pfizer.com.
James R ApgarGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. james.r.apgar@pfizer.com.
Kristine SvensonGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. kristine.svenson@pfizer.com.
Lidia MosyakGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. lidia.mosyak@pfizer.com.
Yinhua YangMacroGenics Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA. yangy@Macrogenics.com.
Gurunadh R ChichiliMacroGenics Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA. chichilig@Macrogenics.com.
Liqin LiuMacroGenics Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA. liul@Macrogenics.com.
Hua LiMacroGenics Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA. lih@Macrogenics.com.
Steve BurkeMacroGenics Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA. burkes@Macrogenics.com.
Syd JohnsonMacroGenics Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA. johnsons@Macrogenics.com.
Ralph AldersonMacroGenics Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA. aldersonr@Macrogenics.com.
William J J FinlayGlobal Biotherapeutics Technologies, Pfizer Inc., Grange Castle Business Park, Clondalkin, Dublin 22, Ireland. jonny.finlay@gmail.com.
Laura LinGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. laura.lin@pfizer.com.
Stéphane OllandGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. stephane.olland@gmail.com.
William SomersGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. will.somers@pfizer.com.
Ezio BonviniMacroGenics Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA. bonvinie@Macrogenics.com.
Hans-Peter GerberOncology Research Unit, Pfizer Inc., 401 N. Middletown Road, Pearl River, NY 10965, USA. hanspeter.geber@pfizer.com.
Chad MayOncology Research Unit, Pfizer Inc., 401 N. Middletown Road, Pearl River, NY 10965, USA. chad.may@pfizer.com.
Paul A MooreMacroGenics Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA. moorep@Macrogenics.com.
Lioudmila TchistiakovaGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. lioudmila.tchistiakova@pfizer.com.
Laird BloomGlobal Biotherapeutics Technologies, Pfizer Inc., 610 Main St., Cambridge, MA 02139, USA. laird.bloom@pfizer.com.
Pfizer (United States) · USMacroGenics (United States) · USPfizer (Ireland) · IE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bispecific antibodies offer a promising approach for the treatment of cancer but can be challenging to engineer and manufacture. Here we report the development of PF-06671008, an extended-half-life dual-affinity re-targeting (DART
Indexed as
bispecificcancerimmuno-oncologyP-cadherinre-targetingT-cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.